Hexahydrocannabinol

Hexahydrocannabinol
Clinical data
ATC code	None;
Legal status
Legal status	UK: Illegal to produce, supply, or sell under the Psychoactive Substances Act 2016; US: Unscheduled; UN: Unscheduled; In general legal.;
Identifiers
	IUPAC name (6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,9,10,10a-hexahydrobenzo[c]chromen-1-ol;
CAS Number	6692-85-9 (unspecified stereochemistry); 946512-74-9 (6aR,10aR);
PubChem CID	16050328;
ChemSpider	13178711;
CompTox Dashboard (EPA)	DTXSID20985587 ;
Chemical and physical data
Formula	C21H32O2
Molar mass	316.485 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCCCCC1=CC(=C2[C@@H]3CC(CC[C@H]3C(OC2=C1)(C)C)C)O;
	InChI InChI=1S/C21H32O2/c1-5-6-7-8-15-12-18(22)20-16-11-14(2)9-10-17(16)21(3,4)23-19(20)13-15/h12-14,16-17,22H,5-11H2,1-4H3/t14?,16-,17-/m1/s1; Key:XKRHRBJLCLXSGE-VNCLPFQGSA-N;

Hexahydrocannabinol (HHC) is a phytocannabinoid that has been reported as a trace component of Cannabis sativa. It can also be synthesized by hydrogenation of tetrahydrocannabinol (THC). The synthesis and bioactivity of HHC was first reported in 1940 by Roger Adams.

HHC is a psychoactive substance with effects reportedly similar to those of THC. HHC vaporizers have been openly sold at head shops and convenience stores since at least the early 2020s in North America and Europe. While HHC has never been approved by any drug regulatory agency, a racemic mixture of epimers has shown in vitro activity against pancreatic ductal adenocarcinoma cell lines.